Menora Mivtachim Holdings LTD. Grows Position in MediWound Ltd. $MDWD

Menora Mivtachim Holdings LTD. lifted its position in shares of MediWound Ltd. (NASDAQ:MDWD) by 348.8% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 78,539 shares of the biopharmaceutical company’s stock after purchasing an additional 61,039 shares during the quarter. Menora Mivtachim Holdings LTD.’s holdings in MediWound were worth $1,415,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in MDWD. BNP Paribas Financial Markets raised its holdings in MediWound by 90.4% in the third quarter. BNP Paribas Financial Markets now owns 1,523 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 723 shares in the last quarter. Russell Investments Group Ltd. boosted its holdings in shares of MediWound by 69.1% during the 2nd quarter. Russell Investments Group Ltd. now owns 1,588 shares of the biopharmaceutical company’s stock valued at $31,000 after buying an additional 649 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of MediWound by 22.4% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 5,452 shares of the biopharmaceutical company’s stock valued at $85,000 after buying an additional 999 shares in the last quarter. Rhumbline Advisers grew its position in shares of MediWound by 4.4% in the 1st quarter. Rhumbline Advisers now owns 11,316 shares of the biopharmaceutical company’s stock worth $176,000 after buying an additional 481 shares during the period. Finally, R Squared Ltd purchased a new stake in shares of MediWound in the 3rd quarter worth about $194,000. 46.83% of the stock is owned by hedge funds and other institutional investors.

MediWound Trading Down 3.7%

MediWound stock opened at $16.58 on Friday. MediWound Ltd. has a 12 month low of $14.14 and a 12 month high of $22.50. The company has a market capitalization of $212.39 million, a price-to-earnings ratio of -7.90 and a beta of 0.13. The business’s fifty day simple moving average is $17.60 and its two-hundred day simple moving average is $17.86.

MediWound (NASDAQ:MDWD) last issued its quarterly earnings results on Thursday, March 5th. The biopharmaceutical company reported ($0.56) earnings per share for the quarter, beating the consensus estimate of ($0.65) by $0.09. The firm had revenue of $1.87 million during the quarter, compared to the consensus estimate of $2.09 million. MediWound had a negative return on equity of 65.79% and a negative net margin of 140.80%. On average, equities research analysts predict that MediWound Ltd. will post -2.66 EPS for the current year.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on the stock. HC Wainwright reiterated a “buy” rating and issued a $36.00 price target (up from $31.00) on shares of MediWound in a research note on Friday, November 21st. Wall Street Zen cut shares of MediWound from a “hold” rating to a “strong sell” rating in a report on Saturday, March 7th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of MediWound in a research note on Thursday, January 22nd. Three research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, MediWound currently has a consensus rating of “Hold” and an average target price of $31.67.

About MediWound

MediWound Ltd. (NASDAQ: MDWD) is a biopharmaceutical company headquartered in Yavne, Israel, specializing in the development and commercialization of innovative enzymatic therapies for burn and wound management. Since its establishment, the company has focused on advancing proteolytic enzyme technology to address critical needs in debridement and tissue repair. MediWound operates research and development facilities in Israel and maintains commercial offices in the United States to support its global market presence.

The company’s lead product, NexoBrid®, is an enzyme-based debriding agent designed to selectively remove burn eschar without harming viable tissue.